Vitamin D3 for Life

Live Enlightened

Article

VDR FokI Polymorphism in Human Breast Cancer Cells: Study Summary

Previous related pageVDR FokI Polymorphism and Immune-Cell Function: Full Evidence ReviewNext related pageVDR FokI, Receptor Expression and Linked Haplotypes: Evidence Synthesis
Study at a glance

Do inherited vitamin D receptor differences affect breast cancer cells?

Researchers compared two inherited forms of the vitamin D receptor, a protein that helps cells respond to active vitamin D. They used human breast cancer cells modified in the laboratory to produce a shorter or longer receptor. They then exposed the cells to the active vitamin D hormone.

How did the breast cancer cells respond to active vitamin D?

Cells with the shorter receptor showed a larger reduction in growth than cells with the longer receptor. They also showed a stronger response in a vitamin D-related gene and a larger fall in an oestrogen receptor protein. The shorter vitamin D receptor was more stable in a separate laboratory test. These differences were observed in this particular cell model.

Did the vitamin D receptor form explain every difference between the cells?

The cells were grown from selected individual cells and deliberately modified. Differences between these cell groups, including how much receptor they produced, could also affect their responses. The study did not establish that the receptor form alone explained every difference.

Does this cell study show that vitamin D can treat breast cancer?

The study did not test treatment in people or show that vitamin D supplements prevent or treat breast cancer. It also did not establish that an inherited receptor form determines cancer risk or disease progression. Responses in laboratory cancer cells cannot be assumed to describe effects throughout the body.

Read the full article below ↓

This page provides a concise summary of a single verified primary study. For full methodological detail, measurement constraints, and inference boundaries, see the Common VDR Polymorphisms and Functional Implications: Full Evidence Review.

Study identity

Study type: Primary experimental laboratory study using engineered human breast cancer cell lines

Population or system studied: MCF-7 human breast cancer cells, including stable single-cell clones expressing defined VDR FokI variants

Primary exposure or variable: Vitamin D receptor FokI genotype variant (VDRff vs VDRFF) with 1α,25-dihydroxyvitamin D3 exposure

Primary outcome category: Functional cellular response and gene expression response to 1α,25(OH)2D3 under defined receptor-variant conditions

Purpose of the study

The study set out to test whether a common VDR start-codon polymorphism (FokI) is associated with functional differences in vitamin D signalling effects in a controlled cellular system. The key framing move is methodological: rather than infer “functional significance” from population associations, the authors built stable cell-line models that differ in the VDR variant they express, then measured whether those variants show different magnitudes of response to the active vitamin D hormone.

Study overview

Researchers generated stable MCF-7 single-cell clones that either carried a control vector, expressed the longer VDR protein form (VDRff), or expressed the shorter form (VDRFF). Cells were then treated with 1α,25(OH)2D3 and evaluated for growth inhibition and selected molecular readouts that reflect VDR-driven transcriptional response.

Key readouts included the magnitude of growth inhibition after hormone exposure, induction of a canonical vitamin D target gene (CYP24A1 mRNA), and changes in estrogen receptor-α protein expression. The study also assessed VDR protein stability under cycloheximide conditions and used a PCR array approach to compare basal expression patterns of selected genes between the variant-expressing cell lines.

Key findings

Under 1α,25(OH)2D3 treatment, VDRFF-expressing cells showed a larger growth-inhibitory response than VDRff-expressing cells in this model system. In parallel, induction of CYP24A1 mRNA was higher in VDRFF cells than in VDRff cells, consistent with a stronger transcriptional response to the hormone under the conditions tested.

The study also reported larger downregulation of estrogen receptor-α protein expression in VDRFF cells than in VDRff cells. In addition, VDR protein stability was described as greater in the VDRFF-expressing cells in the presence of cycloheximide, supporting the possibility that receptor-variant behaviour differs in ways that can matter for the magnitude of downstream responses in this cellular setting.

What this study shows

In a controlled experimental system where the receptor variant is defined and held constant within stable single-cell clones, the two common FokI-linked VDR protein forms can be associated with measurably different response magnitudes to 1α,25(OH)2D3. The specific outputs tested in this study indicate that, at least in this MCF-7 model, the shorter VDR form (VDRFF) aligned with stronger growth inhibition and stronger induction of a canonical vitamin D target gene than the longer form (VDRff).

It also shows that “functional implications” can be operationalised in multiple ways: not only through a growth endpoint, but through receptor-linked transcriptional outputs (CYP24A1 induction), hormone-linked regulation of a major signalling axis in these cells (estrogen receptor-α protein), and stability-related behaviour that can influence effective signalling over time.

What this study does not show

This study does not establish population-level effects of the FokI polymorphism, because it is not a population study. It does not estimate how these variants behave across tissues in vivo, nor does it quantify how genotype effects might be modified by circulating vitamin D status, endocrine dynamics, or cell-type-specific cofactor availability.

It also does not justify extending these specific effect sizes to clinical outcomes. Even where the authors discuss the implications for “aggressive breast cancer” phenotypes, the data remain bounded to this engineered cellular context and the specific endpoints measured. The study tests response magnitude differences under defined conditions; it does not prove that genotype causes particular clinical trajectories.

Relevant measurement framing: Vitamin D Status vs Vitamin D Effect.

Limitations (high level)

The model uses stable single-cell clones derived from a breast cancer cell line, which improves control but limits generalisability. The system focuses on a specific cellular context with a particular transcriptional environment, and the measured outcomes represent only a subset of possible VDR-mediated behaviours.

Differences in measured response magnitude may reflect multiple factors in addition to the receptor protein variant itself, including clone-specific cellular state, expression level differences, and context-dependent co-regulator interactions. The study provides evidence of variant-associated differences in this system; it does not isolate a single mechanistic cause for those differences.

Interpretation within vitamin D physiology

Within a physiology-first framework, this study is best used to support a bounded claim: receptor-genotype-linked structural differences can matter for signalling output magnitude in at least some cellular contexts. That is a different axis from ligand availability or circulating status, and it helps explain why “vitamin D effect” can vary even when the same ligand is applied under controlled conditions.

To understand the receptor layer that sits above these cellular readouts, see Vitamin D Receptors.

For relevant physiology background, see Vitamin D Receptor Polymorphisms.

Relevant genetics layer: Vitamin D Genetics.

Primary source and publication details

Alimirah F, Peng X, Murillo G, Mehta RG, et al.

Functional significance of vitamin D receptor FokI polymorphism in human breast cancer cells

PLOS ONE. 2011.

DOI: 10.1371/journal.pone.0016024

https://pubmed.ncbi.nlm.nih.gov/21283672

Related reading

Library

The ERRα-VDR axis promotes calcitriol degradation and estrogen signaling in breast cancer cells, while VDR‐CYP24A1‐ERRα overexpression correlates with poor prognosis in patients with basal‐like breast cancer

Besides estrogen receptor alpha (ERα), estrogen‐related receptor alpha (ERRα) has also been shown to interfere with the VDR pathway, but its role in the antitumor and transactivation activity of calcitriol is completely unknown in breast cancer (BC).

Original paper ↗Read more →

Original sources